🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer

RecruitingPhase 2, Phase 3Ages 18 Years - 80 YearsAllChang Gung Memorial Hospital
NCT02448992 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background. During the clinical course of patients with locoregionally advanced non-small-cell lung cancer (LA-NSCLC) who have undergone aggressive treatment, brain metastasis (BM) is a frequent seen pattern of disease relapse, which cannot be ignored. It still remains unresolved whether prophylactic cranial irradiation (PCI) via whole brain radiotherapy (WBRT) should be recommended for NSCLC patients with stage III or pathologically nodal positive disease. Actually, PCI would significantly decrease the incidence of BM; however, potential WBRT-related neurocognitive function (NCF) sequelae are indeed a concern, which has made PCI seldom applied in clinical practice. In terms of the time course of WBRT-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involve impairments of episodic

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinical diagnosis of NSCLC * Must be adult patients (≥ 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis * Platinum-based chemotherapy is mandatory * Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) \> 70 % * Should have sufficient proficiency in Mandarin language Exclusion Criteria: * Have received prior cranial irradiation * Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ) * Radiographic evidence of brain metastasis/metastases * Clinical evidence of extracranial metastatic disease * Hypersensitivity to magnetic resonance (MR) contrast enhancer * Serious medical or psychiatric illness
💊

What it tests

  • hippocampal-sparing WBRT
📍

Where

1 site
Chang Gung Memorial Hospital
Taoyuan, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy